Treatment of electrolyte disorders in adult patients in the intensive care unit

MICHAEL D. KRAFT, IMAD F. BTAICHE, GORDON S. SACKS, AND KENNETH A. KUDSK

Electrolytes are involved in many metabolic and homeostatic functions, including enzymatic and biochemical reactions, the maintenance of cell membrane structure and function, neurotransmission, nerve signal conduction, hormone function, muscle contraction, cardiovascular function, bone composition, and fluid and acid–base regulation. In addition to serum electrolyte concentrations, signs and symptoms of specific electrolyte disorders should be monitored in patients with electrolyte abnormalities. The severity of symptoms related to electrolyte disorders generally correlates with the severity of the disorder and the rate at which the disorder developed. Multiple mechanisms may be involved in electrolyte abnormalities in adult patients in the intensive care unit (ICU), including altered absorption and distribution; excessive or inadequate administration; alterations in hormonal, neuro-

Purpose. The treatment of electrolyte disorders in adult patients in the intensive care unit (ICU), including guidelines for correcting specific electrolyte disorders, is reviewed.

Summary. Electrolytes are involved in many metabolic and homeostatic functions. Electrolyte disorders are common in adult patients in the ICU and have been associated with increased morbidity and mortality, as has the improper treatment of electrolyte disorders. A limited number of prospective, randomized, controlled studies have been conducted evaluating the optimal treatment of electrolyte disorders. Recommendations for treatment of electrolyte disorders in adult patients in the ICU are provided based on these studies, as well as case reports, expert opinion, and clinical experience. The etiologies of and treatments for hyponatremia (hypovolemic, isovolemic, and hypervolemic), hypokalemia and hyperkalemia, hypophosphatemia and hyperphosphatemia, hypocalcemia and hypercalcemia, and hypomagnesemia and hypermagnesemia are discussed, and equations for determining the proper dosages for adult patients in the ICU are provided. Treatment is often empirical, based on published literature, expert recommendations, and the patient’s response to the initial treatment. Actual electrolyte correction requires individual adjustment based on the patient’s clinical condition and response to therapy. Clinicians should be knowledgeable about electrolyte homeostasis and the underlying pathophysiology of electrolyte disorders in order to provide the optimal therapy to patients.

Conclusion. Treatment of electrolyte disorders is often empirical, based on published literature, expert opinion and recommendations, and patient’s response to the initial treatment. Clinicians should be knowledgeable about electrolyte homeostasis and the underlying pathophysiology of electrolyte disorders to provide optimal therapy for patients.

Index terms: Calculations; Critical illness; Dosage; Electrolytes; Equations; Methodology; Mortality; Protocols; Water-electrolyte imbalance


Copyright © 2005, American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/05/0802-1663$06.00. DOI 10.2146/ajhp040300
logic, and homeostatic mechanisms; or altered excretion via gastrointestinal (GI) and renal losses, as well as changes in fluid status and fluid shifts. Excessive losses should be corrected by administering the appropriate replacement fluid (i.e., composition of the replacement fluid should match that of the fluid lost) in adequate amounts (e.g., 0.5–1 mL per 1 mL of output) and giving maintenance fluids. Clinicians should always consider the possibility of laboratory error, sampling error, or blood-sample hemolysis before initiating therapy, especially when the patient is asymptomatic and electrolytes were previously normal with little or no change in therapies or clinical condition. If an error is suspected, a repeat analysis should be obtained before treatment. Since the kidney is the major organ involved in fluid and electrolyte homeostasis, very close attention must be given to renal function in all patients before correcting any electrolyte disorder.

The pathophysiology, etiology, and clinical manifestations of specific electrolyte disorders have been thoroughly reviewed. This review focuses on the treatment of such disorders in adult patients in the ICU and is intended to provide clinicians with guidelines for correcting specific electrolyte disorders in these patients by applying estimations based on evidence in the literature and clinical experience. Actual electrolyte correction requires individual adjustment by evaluating the patient’s clinical condition and response to therapy. The equations and recommendations provided are not meant to replace sound clinical judgment and knowledge of electrolyte homeostasis and the underlying pathophysiology of electrolyte disorders.

**Dosing guidelines**

There are limited data and conflicting opinions and recommendations on the dosing of electrolytes in adult patients in the ICU. In addition, there are no definitive recommendations for the optimal dosing weight for adult patients, particularly the obese. Clinicians frequently “adjust” body weight (e.g., using body mass index [BMI] or percent above ideal body weight [IBW]) in patients who are obese; however, there are no data identifying the optimal way to estimate this adjusted weight. Furthermore, there is considerable debate as to what degree of obesity the clinician should consider to use an adjusted body weight or how to appropriately adjust body weight to optimize dosing and minimize the risk for overdose and associated adverse effects. Total body water in men is slightly higher than that in women, and it is estimated that adipose tissue is composed of approximately 10–30% water. Therefore, we suggest using an adjusted body weight (AdjBW) in obese adult patients (i.e., actual weight > 130% of IBW or BMI > 30 kg/m²) when weight-based dosing is required using the following calculations:

\[
\text{AdjBW (men)} = (\text{weight in kg} - \text{IBW in kg}) \times 0.3 + \text{IBW}
\]

\[
\text{AdjBW (women)} = (\text{weight in kg} - \text{IBW in kg}) \times 0.25 + \text{IBW}
\]

**Sodium**

Sodium is the most abundant extracellular cation and has a normal serum concentration of 135–145 meq/L. Normal homeostatic mechanisms keep the serum sodium concentration and serum osmolality (275–290 mosmole/kg water) within narrow therapeutic ranges. Osmotic pressure and osmolality determine the distribution of water between various body compartments, with sodium being the major osmotically active substance in the extracellular fluid. Water will flow from the compartment with lower osmolality to the compartment of higher osmolality until osmotic equilibrium is achieved. Serum osmolality can be measured directly or calculated using the following equation:

\[
\text{Serum osmolality (mosmole/kg in water)} = (2 \times \text{serum sodium conc. in meq/L}) + (\text{serum urea conc. in mg/dL/2.8}) + (\text{serum glucose conc. in mg/dL/18})
\]

Changes in serum sodium concentration usually reflect changes in water balance; however, total body sodium concentration may be increased, decreased, or normal. Therefore, volume status must also be assessed in patients with hyponatremia or hypernatremia before initiating treatment. Rose and Post have written an excellent review and discussion of the concepts of sodium and water balance and plasma osmolality.

Sodium imbalances are common in ICU patients, yet often poorly understood. Caution must be exercised to avoid inappropriate correction of the sodium imbalance, which could result in further complications, morbidity, and death.

**Hyponatremia.** Hyponatremia (serum sodium concentration of <135 meq/L) may reflect increased, decreased, or normal total body sodium concentrations and necessitates assessment of serum osmolality. As hypoosmolar (hypotonic) hyponatremia can develop in the presence of hypovolemia, isoosmolemia, or hypervolemia, the patient’s fluid volume must also be assessed. The potential etiologies of hyponatremia are numerous, depending on the patient’s serum osmolality and fluid volume (Figure 1).

The signs and symptoms of hyponatremia are often nonspecific, and most are related to the change in serum osmolality and consequent fluid shifts in the central nervous system (CNS). These signs and symptoms can include headache, lethargy, disorientation, restlessness, nausea, vomiting, muscle cramps or weakness, depressed reflexes, seizures,
Electrolyte disorders

Figure 1. Classification and common etiologies of hyponatremia.\textsuperscript{1,6,8,9} NSAIDs = nonsteroidal antiinflammatory drugs.

CLINICAL REVIEW  Electrolyte disorders

SYMPTOMS DEVELOPING IN PATIENTS

RATE OF DEVELOPMENT AND SEVERITY OF SYMPTOMS IS RELATED TO THE ETIOLOGY OF THE HYponatraEMIA

MORBIDITY AND MORTALITY MAY BE DUE TO HYponatraEMIA ITSELF, THE UNDERLYING DISEASE STATE, OR THE INAPPROPRIATE TREATMENT OF HYponatraEMIA. PROPER TREATMENT DEPENDS ON PROMPT AND APPROPRIATE IDENTIFICATION, DIAGNOSIS, AND CLASSIFICATION AND IS BASED ON THE PATIENT’S SERUM OSMOLALITY AND FLUID VOLUME.
Symptomatic hyponatremia. Severe symptomatic hyponatremia (e.g., altered mental status, seizures) requires prompt correction with free-water restriction and i.v. administration of hypertonic saline (e.g., 3% sodium chloride injection = 512 meq sodium/L) at a rate of 15–80 mL/hr9,11,69 or up to 1–2 mL/kg/hr for two to three hours,8,11 with the possible addition of a loop diuretic (e.g., furosemide) in nonhypovolemic patients.11,70 Reversible causes of hyponatremia (e.g., excessive i.v. administration of hypotonic fluids, such as 5% dextrose injection) should first be identified and corrected with the restriction of hypotonic fluids.

The approximate sodium deficit should be calculated to estimate replacement needs using the following equation:

$$\text{Sodium deficit (meq)} = \text{TBW} \times \left(140 - \text{measured serum sodium conc.}\right),$$

where

$$\text{TBW} \ (\text{men}) = 0.6 \ \text{L/kg} \times \text{weight in kg}$$
$$\text{and TBW} \ (\text{women}) = 0.5 \ \text{L/kg} \times \text{weight in kg}$$

The estimated percentage of body water for normal men is 60% (0.6) and the estimated percent body water for normal women is 50% (0.5). These percentages are often higher in ICU patients. We suggest using the AdjBW to calculate the sodium deficit of patients who are significantly obese.

Serum sodium concentrations should be corrected at a rate of 1–2 meq/L/hr for patients with symptomatic hyponatremia or severe acute hyponatremia (e.g., change in serum sodium concentration of >0.5 meq/L/hr or onset in less than 48 hours10,55,56,58,60,72) and no faster than 0.5 meq/L/hr when hyponatremia is chronic (i.e., develops over more than two or three days) or when the time over which the hyponatremia developed is unknown.54,55,58,61,63 The maximum recommended increase in serum sodium concentration is 8–12 meq/L per 24 hours,9,54,55,59,61,65 with complete correction over 48–96 hours. Fifty percent of the estimated sodium deficit is usually administered over the first 24 hours and the remainder over the next 24–72 hours. A reasonable short-term treatment goal is to correct the serum sodium to 120–130 meq/L,55,56,61,63,65,72,73 or lower in patients whose serum sodium concentration is ≤105 meq/L.55,63,65,72,73 Serum sodium concentration should not be corrected initially to more than 135 meq/L and should not exceed the upper limit of normal (145 meq/L) at any time during treatment. Serum sodium levels should be monitored frequently (e.g., every 2–4 hours) until the patient is asymptomatic, then every 4–8 hours until the serum sodium is within the normal range. Overly rapid correction of serum sodium levels can induce neurologic complications, including central pontine myelinolysis,53,59,61,64 which manifests clinically as a gradual onset of neurologic alterations occurring within one to six days of rapid correction. Findings may include pseudobulbar palsy, quadripareisis, seizures, and movement disorders.

Alternatively, one can estimate the anticipated change in serum sodium levels after i.v. infusion of 1 L of 3% sodium chloride injection using the following equation69:

$$\text{Change in serum sodium conc.} = \frac{(512 \ \text{meq/L} - \text{serum sodium conc.})}{\text{TBW}} + 1$$

and after i.v. infusion of 1 L of 0.9% sodium chloride injection with the following equation69:

$$\text{Change in serum sodium conc.} = \frac{(154 \ \text{meq/L} - \text{serum sodium conc.})}{\text{TBW}} + 1$$

With this calculation, initiation of 3% sodium chloride injection at 15–50 mL/hr may be an appropriate starting point (depending on the severity of hyponatremia). Adjustments should be based on the patient’s response and calculated with the above equations.

Hypovolemic hypotonic hyponatremia. In patients with hypovolemic hypotonic hyponatremia, the approximate sodium deficit should be calculated to estimate replacement needs and corrected with 0.9% sodium chloride injection or lactated Ringer’s solution according to guidelines for rate of correction and monitoring discussed previously.

Isovolemic hypotonic hyponatremia. Isovolemic hypotonic hyponatremia is treated with water restriction. Mild diuresis with a loop diuretic (e.g., i.v. furosemide 20–40 mg every 6–12 hours) may also be helpful. Syndrome of inappropriate antidiuretic hormone (SIADH) is the most common cause of isovolemic hypotonic hyponatremia. SIADH is characterized by an inappropriate response of antidiuretic hormone (ADH) to any volume or osmotic stimuli that normally affect ADH secretion. There may be increased ADH release or increased kidney response to ADH. Patients are hyponatremic in the setting of serum hypotonicity (<270 mosmole/L) and do not have evidence of edema or pituitary, thyroid, adrenal, cardiac, renal, or hepatic dysfunction.3,6,8 Patients have impaired free-water excretion, with normal excretion of sodium. The urine is inappropriately concentrated (>100 mosmole/kg) with an increase in urine sodium concentration of greater than 20–30 meq/L.3,6,8 The continued intake of water (or hypotonic fluids) will ultimately lead to the development of hyponatremia. Numerous conditions and medications may induce SIADH (Figure 1). In the case of drug-induced SIADH, the suspected agent should be discontinued, if possible. The primary acute therapy for SIADH is correction of the underly-
Electrolyte disorders

Osmolality. Therefore, hyponatremia does not contribute to the effective osmolality. Because urea disperse freely across membranes and is considered an ineffective osmole, it does not contribute to the effective osmolality. Therefore, hyponatremia in patients with renal failure is usually classified as hypotonic because the effective serum osmolality is generally reduced.

Treatment includes optimizing treatment of the underlying cause, in addition to sodium and fluid restriction (e.g., 1000–1500 mL daily) and diuresis with a loop diuretic (e.g., furosemide).

Isotonic hyponatremia and hypertonic hyponatremia. Therapy for isotonic hyponatremia and hypertonic hyponatremia should be aimed at identifying and correcting the underlying cause. Hypertonic hyponatremia may result from hyperglycemia or administration of hypertonic sodium-free solutions. Hyperglycemia causes a shift of water out of cells into the extracellular space, resulting in dilution of serum sodium. For every 100-mg/dL increase in serum glucose concentration above 100 mg/dL, the serum sodium concentration would be expected to decrease by approximately 1.6 meq/L. Therefore, the corrected serum sodium concentration should be calculated using the following equation before attempting the correction:

\[
\text{Corrected serum sodium conc.} = \frac{\text{serum sodium conc.} + 1.6(\text{serum glucose conc. } - 100)}{100}
\]

Infusion of any sodium-free isotonic or hypertonic solutions (e.g., mannitol) should be stopped if clinically appropriate. Hyperglycemia should be controlled with insulin therapy (e.g., sliding-scale regular insulin or continuous i.v. infusion) and by avoiding excessive carbohydrate loads. Serum sodium levels should be monitored as previously described.

Pseudohyponatremia. Pseudohyponatremia occurs when there is an increase in the nonaqueous portion of the serum, such as with hyperlipidemia and hyperproteinemia. This is not a true hyponatremia, since the sodium concentration in the aqueous portion of the serum remains normal. Pseudohyponatremia has been historically related to the older method for measuring serum sodium levels using flame-emission spectrophotometry. This method has largely been replaced with a more specific technique that uses sodium-selective electrodes to measure serum sodium. However, this new technique may not completely eliminate the problem, and serum osmolality should be measured in patients with hyponatremia.

Hypernatremia. Hypernatremia (serum sodium concentration of >145 meq/L) reflects a water deficit relative to total body sodium levels and is associated with serum hypertonicity. Total body sodium may be increased, decreased, or normal, and assessment of the patient’s volume status is required. There are several potential etiologies of hypernatremia, depending on the alteration in the patient’s volume status (Table 1). Generally, hypernatremia develops when the thirst mechanism is not functioning normally or if access to free water is limited or controlled. The latter occurs in acutely ill ICU patients when fluid intake is controlled or restricted.

Table 1. Classification and Common Etiologies of Hypernatremia

<table>
<thead>
<tr>
<th>Classification</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemic</td>
<td>Loss of hypotonic fluids (vomiting, diarrhea, nasogastric suctioning, osmotic diuresis, burns and open wounds, sweat, lungs)</td>
</tr>
<tr>
<td>Isovolemic</td>
<td>Diabetes insipidus (central diabetes, nephrogenic diabetes insipidus)</td>
</tr>
<tr>
<td>Hypervolemic</td>
<td>Hypotonic saline solutions, sodium bicarbonate solutions, mineralocorticoid excess (hyperaldosteronism)</td>
</tr>
</tbody>
</table>
Similar to hyponatremia, the signs and symptoms of hypernatremia can be nonspecific, and most are related to changes in serum osmolality in the CNS. Clinical manifestations of hypernatremia in adults can include lethargy, irritability, restlessness, thirst, muscle irritability and spasticity, hyperreflexia, seizures, coma, and death. Evidence of hypovolemia or hypervolemia may be present. Severity of symptoms may also correlate with severity and the rate of development of hypernatremia.7,14

Hypernatremia is associated with increased morbidity and mortality.6,94-96 The overall mortality rate in adult patients with hypernatremia is approximately 40–70%.94-96 Although the mortality rate directly attributed to hypernatremia itself is likely lower,95 Adults with a serum sodium concentration of >160 meq/L have a mortality rate of >75%.6,94 Mortality associated with chronic hypernatremia is lower than with acute hypernatremia.6,94 Morbidity and mortality associated with hypernatremia are often due to the underlying disease process or inappropriate treatment of the disorder.94,95 Therefore, prompt assessment, diagnosis, and proper therapy of hypernatremia are essential.

Proper treatment depends on the characterization of hypernatremia (hypovolemic, isovolemic, or hypervolemic) and its magnitude, length of time over which it developed, and the severity of symptoms. All reversible causes should be identified and corrected. Administration of sodium (e.g., hypertonic saline or sodium bicarbonate) should be discontinued or reduced if clinically appropriate, the sodium concentration of i.v. fluids should be lowered (e.g., 0.225% sodium chloride injection or 5% dextrose injection), and medication solvents should be changed to 5% dextrose injection, if compatible. If hypernatremia developed rapidly (i.e., over a period of hours), correction is usually well tolerated because brain cells have not yet fully adapted to the imbalance.2 However, the mortality rate increases with more rapid correction of hypernatremia.94 Therefore, in the case of acute hypernatremia, the serum sodium concentration should be corrected no faster than 1–2 meq/L/hr to avoid cerebral edema.8,14,97 Extreme caution is warranted in the case of chronic hypernatremia or if hypernatremia developed over an unknown length of time, because rapid correction can result in brain edema, swelling, herniation, and death.2 In these cases, the serum sodium concentration should be corrected at a maximum rate of 0.5 meq/L/hr.14,98

The anticipated change in serum sodium levels after i.v. infusion of 1 L of 5% dextrose injection can be estimated using the following equation69:

\[ \text{Change in serum sodium conc.} = \left( 0 \ \text{meq/L} - \text{serum sodium conc.} \right) / \left( \text{TBW + 1} \right) \]

and after i.v. infusion of 1 L of 0.225% sodium chloride injection with the following equation69:

\[ \text{Change in serum sodium conc.} = \left( 38.5 \ \text{meq/L} - \text{serum sodium conc.} \right) / \left( \text{TBW + 1} \right) \]

and after i.v. infusion with 1 L of 0.45% sodium chloride injection with the following equation:

\[ \text{Change in serum sodium conc.} = \left( 154 \ \text{meq/L} - \text{serum sodium conc.} \right) / \left( \text{TBW + 1} \right) \]

Alternatively, the relative water deficit associated with hypernatremia can be estimated using the following equation:

\[ \text{Water deficit (in liters)} = \text{TBW} \times \left[ \frac{\text{serum sodium conc.}}{140} - 1 \right] \]

Half of the water deficit should be replaced over the first 24 hours, and the remainder replaced over the following 24–72 hours, with the total correction taking place over 48–96 hours.8,14,95,97 Serum sodium concentration should be decreased by a maximum of 10–12 meq/L per 24 hours.14,98 When the patient is hypovolemic or hypotensive, isotonic 0.9% sodium chloride injection or lactated Ringer’s solution should be used to help correct the hemodynamic instability. Otherwise, 5% dextrose injection or a hypotonic saline solution (0.225% or 0.45% sodium chloride injection) can be used.

Patients with symptomatic hypernatremia (e.g., altered mental status, seizures, coma) should have their sodium levels monitored every 2–4 hours. Once symptoms resolve, serum sodium should be monitored frequently (i.e., every 4–8 hours) until normal. A goal serum sodium concentration of 145 meq/L has been suggested.14

**Hypovolemic hypernatremia.** The water deficit associated with this condition should be calculated. After correcting the initial hypovolemia with 0.9% sodium chloride injection or lactated Ringer’s solution in hemodynamically unstable patients, the water deficit should be corrected with a hypotonic solution. The appropriate type and amount of maintenance fluid should be provided, along with treatment of the deficit to prevent further dehydration.

**Isovolemic hypernatremia.** Isovolemic hypernatremia can result from a relative water deficit (i.e., free-water or hypotonic sodium losses) or relative sodium excess (e.g., isotonic sodium administration [0.9% sodium chloride injection] for hypotonic losses, such as those through the skin). The relative water
Electrolyte disorders

Hypokalemia. Hypokalemia is defined as a serum potassium concentration below 3.5 meq/L and considered severe if below 2.5 meq/L or if a patient is symptomatic. Because hypokalemia results in membrane hyperpolarization and impaired muscular contraction, its signs and symptoms generally involve changes in muscle and cardiovascular function. Patients with mild hypokalemia (e.g., serum potassium approximately 3–3.4 meq/L) may be asymptomatic. Signs and symptoms of hypokalemia include nausea, vomiting, weakness, constipation, paralysis, respiratory compromise, and rhabdomyolysis. The most severe and concerning adverse effects related to hypokalemia are electrocardiogram (ECG) changes, cardiac arrhythmias, and sudden death, especially in patients with hypertension, myocardial ischemia, or heart failure. ECG changes can include ST-segment depression, T-wave flattening, T-wave inversion, and the presence of U waves.

Hypokalemia can develop in ICU patients as a result of intracellular shifts of potassium, increased losses of potassium, or, less commonly, decreased ingestion or administration of potassium. Serum potassium levels do not correlate well with intracellular potassium levels and may not correlate with total body potassium. Therefore, hypokalemia may not imply a depletion of body potassium stores. Potassium supplementation and dosing are largely empirical and guided by serum potassium levels. It has been estimated that for every 0.3–meq/L decrease in serum potassium concentration, the total body potassium deficit is approximately 100 meq. Critically ill patients may have underlying conditions or receive medications that can cause hypokalemia. Metabolic alkalosis causes an intracellular shift of potassium; however, the total body potassium level will not change. Correction of the underlying metabolic alkalosis should result in redistribution of po-
Electrolyte disorders

Potassium phosphate is used to correct coexisting hypokalemia and hypophosphatemia. We recommend an initial i.v. potassium dose of 20–40 meq for an ICU patient with mild to moderate hypokalemia (serum potassium concentration = 2.5–3.4 meq/L) (Table 2). Patients with symptomatic or severe hypokalemia (serum potassium concentration of <2.5 meq/L) require more aggressive therapy with initial i.v. potassium doses of up to 40–80 meq. Patients with impaired renal function should receive no more than 50% of the recommended initial potassium dose. Multiple doses of potassium can be repeated to normalize serum potassium concentrations if necessary; however, serum potassium levels should be checked after a total dose of 60–80 meq before further potassium is administered (within one to four hours after dose administration). Potassium should never be administered as a rapid infusion because of the risk of serious or fatal consequences. Intermittent potassium dosing can be safely achieved at potassium infusion rates of 10–20 meq/hr. If an infusion rate exceeding 10 meq/hr is needed, continuous cardiac monitoring is recommended to detect any signs of hyperkalemia, and infusion via a central venous catheter is recommended to minimize infusion-related burning and phlebitis. Potassium infusion rates exceeding 20 meq/hr are rarely needed. In critical situations, infusion rates as high as 40 meq/hr have been used but should be reserved for emergent cases or symptomatic patients.

Goals of therapy for hypokalemia include avoidance or resolution of symptoms, returning the serum potassium concentration to the normal range (i.e., 3.5–5 meq/L), and avoiding hyperkalemia. Hypokalemia is treated by administering oral or i.v. potassium supplements. I.V. potassium supplementation (as chloride, acetate, or phosphate salts) is reserved for the treatment of severe hypokalemia, symptomatic hypokalemia, or when the GI tract cannot be used, and ICU patients may often have one or more of these conditions. Oral potassium supplements are available as chloride, bicarbonate, citrate, gluconate, and phosphate salts. The most commonly used oral or i.v. supplement is potassium chloride. Potassium acetate and bicarbonate can be used when the correction of acidemia is also desired. Potassium phosphate is used to correct coexisting hypokalemia and hypophosphatemia.

Potassium concentration in solutions for continuous infusion via a peripheral vein should be limited to 80 meq/L. Potassium concentrations of up to 120 meq/L can be used for central-vein infusion. I.V. potassium should be diluted in an appropriate diluent before infusion, preferably saline solutions. Dextrose-containing vehicles should be avoided, as they may worsen the hypokalemia by stimulating insulin release that will cause intracellular shifting of potassium. Potassium infusion via a peripheral vein may cause burning pain and phlebitis at the infusion site. Adding 1 mL of 1% lidocaine to a potassium solution of 10–20 meq/100 mL may minimize the pain at the infusion site. However, this could mask a sign of underlying venous damage.

Oral potassium chloride supplements are available in capsule, tablet, or liquid (liquid, powder for solution) formulations, but liquid formulations have an unpleasant taste. Liquid formulations may be inappropriate (and preferred) for critically ill patients with a functional GI tract if a nasoenteric tube is in place. Extended-release oral formulations are also available. The controlled-release microencapsulated tablet appears to be better tolerated and causes less GI erosion than the extended-release wax-matrix tablet. However, if the patient cannot swallow or receive oral medications, this may not be a therapeutic option. Oral potassium dosages of 40–100 meq daily are usually sufficient to correct hypokalemia. The total daily dosage should be divided into two to four doses to avoid adverse GI effects. An oral potassium dosage of 20 meq daily has been suggested to prevent hypokalemia in patients receiving chronic diuretic therapy. Patients in the ICU who receive higher or more frequent doses of potassium-wasting diuretics

| Table 2. Empirical Treatment of Hypokalemia |
|-------------------------------|-----------------|-----------------|
| **Severity**                  | **Serum Potassium Concentration (meq/L)** | **I.V. Potassium Replacement Dose (meq)** |
| Mild to moderate              | 2.5–3.4         | 20–40           |
| Severe                        | <2.5            | 40–80           |

*In patients with normal renal function; patients with renal insufficiency should receive ≤50% of the initial empirical dose. Rate of infusion = 10–20 meq potassium per hour; maximum infusion rate = 40 meq potassium per hour. Continuous cardiac monitoring and infusion via a central venous catheter are recommended for infusion rates >10 meq potassium per hour. Maximum potassium = 80 meq/L via a peripheral vein; up to 120 meq/L via a central vein (admixed in 0.9% or 0.45% sodium chloride injection).
may require i.v. therapy with higher doses. An alternative therapy to potassium supplementation in correcting or preventing hypokalemia is the use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), which are especially useful in patients receiving drugs known to deplete potassium. However, in the acute setting, these agents may not be as effective as other agents (e.g., furosemide) in adult ICU patients when large volumes of excess fluid must be removed and excreted. In addition, the longer time to onset of these medications may be a limitation in treating acute hypokalemia.

Magnesium is important in the regulation of intracellular potassium. Hypomagnesemia may result in refractory hypokalemia, likely due to accelerated renal potassium loss or impairment of sodium–potassium pump activity. When hypokalemia and hypomagnesemia coexist, magnesium deficiency should be corrected to facilitate the correction of hypokalemia.

Serum potassium levels should be monitored frequently (every 1–6 hours) in patients with severe hypokalemia if symptoms are present or if aggressive i.v. treatment is ongoing. Monitoring of serum potassium after i.v. repletion in ICU patients with mild to moderate hypokalemia (within 2–8 hours) may be appropriate, in addition to routine monitoring (e.g., every 24–48 hours). The response to oral potassium repletion is generally delayed compared to i.v. repletion, and routine monitoring may be appropriate if hypokalemia is not severe and the patient is asymptomatic.

**Hyperkalemia.** Hyperkalemia (serum potassium concentration of >5.0 meq/L) can become life threatening when the serum potassium concentration exceeds 6.5 meq/L. Clinical manifestations of hyperkalemia are related to changes in neuromuscular and cardiac function. Patients are often asymptomatic until the serum potassium concentration exceeds 5.5 meq/L. Signs and symptoms of hyperkalemia include muscle twitching, cramping, weakness, ascending paralysis, ECG changes (e.g., tall peaked T-waves, prolonged PR-interval, widened QRS complex, shortened QT-interval) and arrhythmias (e.g., bradycardia, ventricular fibrillation, asystole).

Similar to hypokalemia, true hyperkalemia can develop due to extracellular shifts of potassium, increased potassium ingestion, or impaired potassium elimination. Pseudohyperkalemia can be an artifact of hemolysis from a traumatic blood draw or when the blood sample is contaminated with infused potassium. As such, when a serum potassium level is inappropriately elevated for the clinical situation, the blood test must be repeated to confirm the diagnosis and avoid unnecessary or inappropriate treatment of hyperkalemia.

Hyperkalemia is most commonly seen in the setting of renal insufficiency, and acute renal failure is frequently seen in ICU patients. Potassium-sparing diuretics, angiotensin-converting-enzyme inhibitors, nonsteroidal antiinflammatory drugs, and hypoaldosteronism can impair potassium excretion and cause hyperkalemia. Metabolic acidosis results in an extracellular shift of potassium, without changes in total body potassium. Correction of the underlying metabolic acidosis redistributes potassium into the intracellular space and corrects the hyperkalemia. Other causes of extracellular shifts of potassium include succinylcholine, β-adrenergic blockers, digoxin overdose, and muscular injury (e.g., trauma, rhabdomyolysis).

The goals of the hyperkalemia therapy are to antagonize the cardiac effects of potassium, reverse symptoms (if present), and return serum potassium to normal while avoiding overcorrection. All sources of exogenous potassium should be discontinued, and potassium-sparing diuretics and other medications that can cause hyperkalemia should be stopped, or the dosages decreased, if feasible. Table 3 lists therapies for the treatment of hyperkalemia. I.V. calcium (e.g., calcium gluconate) should be given to symptomatic patients or those with ECG changes, with the calcium dose repeated as needed based on the ECG changes. However, this is a temporary treatment to antagonize the effects of potassium and will not remove potassium from the body.

In patients without symptoms, rapid correction of hyperkalemia can be achieved by promoting intracellular distribution with insulin and dextrose, sodium bicarbonate, or albuterol. Sodium bicarbonate should be used with caution in patients with heart failure or renal failure due to its sodium content, which could exacerbate fluid retention in these patients. These therapies can have a rapid effect; however, they only cause a temporary redistribution of potassium to the intracellular space and do not change total body potassium levels.

Further therapies aimed at increasing potassium elimination from the body include potassium-wasting diuretics, sodium polystyrene sulfonate, and renal replacement therapy. Administration of a loop diuretic enhances renal potassium elimination. Sodium polystyrene sulfonate, a cation-exchange resin, binds potassium in the GI tract and eliminates it from the body. Caution should be used when giving sodium polystyrene sulfonate to patients with heart failure or severe hepatic disease because of the drug’s sodium content. Necrosis of the GI tract has been reported in patients who received sodium polystyrene sulfonate in sorbitol. Sorbitol, used as a diluent to counteract constipation with sodium polystyrene sulfonate, is believed to be an important factor in inducing necrosis. As such, sodium polystyrene sulfonate in sorbitol should be used with extreme caution, or
Electrolyte disorders

many therapies for acute hyperkalemia, keeping in mind that symptomatic patients with severe hy-
treatment (every 1–6 hours) in monitored frequently throughout difficult.
In addition, renal replacement thera-
not be seen for several hours. Removes 0.5–1 meq of potassium per 1 g of sodium polystyrene sulfonate.

<table>
<thead>
<tr>
<th>Table 3. Treatments for Hyperkalemia19,20,23</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td>Calcium gluconate&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sodium bicarbonate&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Insulin (regular)&lt;sup&gt;a&lt;/sup&gt; (with dextrose)</td>
</tr>
<tr>
<td>50% dextrose</td>
</tr>
<tr>
<td>10% dextrose</td>
</tr>
<tr>
<td>Furosemide</td>
</tr>
<tr>
<td>Sodium polystyrene sulfonate&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Albuterol</td>
</tr>
<tr>
<td>Hemodialysis</td>
</tr>
</tbody>
</table>

<sup>a</sup>First-line therapies in hyperkalemic emergencies.

<sup>b</sup>Repeat dose in five minutes if abnormal electrocardiogram persists. Calcium chloride may also be used, but calcium gluconate is preferred over calcium chloride for peripheral venous administration because it causes less venous irritation. Calcium chloride (1000 mg = 13.6 meq calcium) provides three times more calcium than calcium gluconate (1 g = 4.56 meq calcium).

<sup>c</sup>Can be used to treat acute hyperkalemia, but the effects may not be seen for several hours. Removes 0.5–1 meq of potassium per 1 g of sodium polystyrene sulfonate.

<sup>d</sup>NA = not applicable.

avoided, especially in uremic patients under stress or with critical illness,113,116,118 patients with hypoten-
and patients with GI obstruction or decreased GI motility.119 Renal re-
therapy is indicated if hyperkalemia is associated with renal failure or if potassium-wasting di-
uretics or sodium polystyrene sul-
fails.18 Renal replacement therapy can be used as part of the initial treatment regimen for acute hyperkalemia and will permanently remove potassium from the body, but the effects of potassium removal and lowered serum potassium levels may not be seen for several hours. In addition, renal replacement ther-
more invasive and technically difficult.

Serum potassium should be monitored frequently throughout treatment (every 1–6 hours) in symptomatic patients with severe hyperkalemia, keeping in mind that many therapies for acute hyperkalemia will only redistribute potassium and not remove it from the body. Continued monitoring of serum po-
tassium levels in patients with hyperkalemia after resolution of symptoms is recommended after therapeutic inter-
ventions every 4–12 hours until serum potassium levels return to normal. Routine monitoring of se-
rum potassium levels (every 24–48 hours) is also recommended in adult patients in the ICU.

**Phosphorus**

Phosphorus is the main intracel-
lar anion. The normal serum con-
centration of phosphorus is 2.7–4.5 mg/dL; however, the majority of phosphorus in the body exists in the bones and soft tissues, with approxi-
mately 1% of total body phosphorus in the extracellular fluid.24,25,27,28
Therefore, serum phosphorus levels may not reflect total body phosphorus levels. Phosphorus exists primarily as phosphate in the serum and has many important functions, in-
cluding bone composition, cell membrane composition, nerve conduc-
tion, and muscle function.24,25,27,28

It provides energy-rich bonds in the form of adenosine triphosphate (ATP) and is required in all physio-
logical, homeostatic, and metabolic functions that require energy. This is especially important in critically ill patients in the ICU, who often experi-
ence hypermetabolism and may have higher phosphorus require-
mances. Adequate total body phosphorus and phosphate are necessary for glucose utilization, glycolysis,
ATP synthesis, numerous biochemi-
cal reactions, 2,3-diphosphoglycerate synthesis and function (which are necessary for oxygen release from hemoglobin and delivery to tissues),
neurologic function, and muscular function (especially the myocardium and diaphragm).24,25,27,28,121–124

**Hypophosphatemia.** Hypophos-
phatemia (serum phosphorus concentra-
tion of <2.7 mg/dL) can lead to severe clinical sequelae, including

1672 | Am J Health-Syst Pharm—Vol 62 Aug 15, 2005
Electrolyte disorders

Impaired diaphragmatic contractility and acute respiratory failure, tissue hypoxia, decreased myocardial contractility, paralysis, weakness, paresthesias, neurologic dysfunction, seizures, and death.24,25,27,28,121-128 Critically ill adult patients in the ICU often have underlying conditions that predispose them to developing hypophosphatemia (malnutrition, inadequate body phosphorus stores or inadequate phosphate administration, alkalosis [respiratory and metabolic], diabetic ketoacidosis, alcoholism, vomiting or gastric losses) or receive therapies or medications that can cause hypophosphatemia if an adequate amount of phosphate is not supplied, especially in malnourished patients who are at risk for developing severe hypophosphatemia and refeeding syndrome.30,121,122,125-128

Given the potential adverse effects of hypophosphatemia, serum phosphorus concentrations in critically ill patients should be maintained within the normal range. Treatment of hypophosphatemia depends on the magnitude of hypophosphatemia and whether or not the patient is symptomatic. Asymptomatic mild hypophosphatemia may be treated with oral phosphate supplementation if the GI tract is functional. However, oral phosphate supplements may cause diarrhea, and oral absorption may be unreliable. Patients with symptomatic, moderate, or severe hypophosphatemia, along with patients who cannot tolerate oral supplements or receive oral medications, should receive i.v. phosphate supplementation to correct serum phosphorus levels. These conditions can be seen frequently in critically ill patients in the ICU. Estimating the appropriate dosage of phosphate is largely empirical because serum concentrations may not correlate with total body stores. Table 4 provides suggested dosages of i.v. phosphate for hypophosphatemia in patients with normal renal function.129-135 In patients with impaired renal function who are not being treated with CRRT, we recommend administering ≤50% of the initial empirical phosphate dosage. Patients being treated with CRRT may require higher initial dosages (i.e., closer to empirical doses used for patients with normal renal function), depending on the severity of hypophosphatemia, the amount of phosphate being removed with CRRT, and whether or not phosphorus is used in the dialysate or replacement fluid. We recommend using AdjBW in significantly obese patients to minimize the risk of overdosing and subsequent hyperphosphatemia. Further supplementation in all cases should be guided by clinical response to the initial dosage.

The i.v. phosphate preparations used are available as the potassium or sodium salts. Potassium phosphate can be used in patients with simultaneous hypokalemia; otherwise, sodium phosphate is recommended. Clinicians must also be aware of the potassium and sodium content of these preparations. One millimole of potassium phosphate contains 1.47 meq of potassium, and 1 mmol of sodium phosphate contains 1.33 meq of sodium. Total phosphate doses are usually infused over four to six hours to minimize infusion-related adverse effects (e.g., thrombophlebitis from potassium phosphate) and to reduce the risk of calcium–phosphate precipitation. However, doses can be infused up to a rate of 7 mmol of phosphate per hour.134,135 Phosphorus can quickly shift between compartments within the body and serum concentrations can fluctuate24,28,129, therefore, a repeat serum phosphorus level should be checked two to four hours after administering a dose. Additional phosphate supplements should be given until the patient is asymptomatic and the serum phosphorus concentration is at least >2.0 mg/dL, with a final goal of returning the serum phosphorus levels to within normal range.

Increasing total caloric load has been associated with reduced serum phosphorus levels in patients receiving parenteral nutrition.121 It is necessary to provide approximately 10–15 mmol of phosphate per 1000 kcal to maintain normal serum phosphorus levels.121 Severely malnourished patients will likely have higher daily phosphate requirements and should be supplemented accordingly. Critically ill patients may also require additional supplementation or adjustment of parenteral nutrition formulations to meet daily phosphorus requirements.

Patients with refractory hypophosphatemia may require a daily phosphate supplementation of phosphate (1) as an oral powder for solution three or four times daily after meals and at bedtime, (2) as an i.v. supplement, or (3) by increasing the

<p>| Table 4. Empirical Treatment of Hypophosphatemia129-135 |
|---------------------------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Serum Phosphorus Concentration (mg/dL)</th>
<th>I.V. Phosphate Replacement Dose (mmol/kg)a,b</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3–2.7</td>
<td>0.08–0.16</td>
</tr>
<tr>
<td>1.5–2.2</td>
<td>0.16–0.32</td>
</tr>
<tr>
<td>&lt;1.5</td>
<td>0.32–0.64</td>
</tr>
</tbody>
</table>

aIn patients with normal renal function; patients with renal insufficiency should receive ≤50% of the initial empirical dose. Maximum infusion rate = 7 mmol phosphate per hour.

bThe authors suggest using adjusted body weight (AdjBW) in patients who are significantly obese [weight of >130% of ideal body weight (IBW) or have a body mass index of ≥30 kg/m²]: AdjBW (men) = [(wt (kg) – IBW (kg)) × 0.3] + IBW; AdjBW (women) = [(wt (kg) – IBW (kg)) × 0.25] + IBW.
maintenance amount in parenteral nutrition.

Well-nourished patients receiving nutrition support should have their serum phosphorus levels monitored daily or every other day. Malnourished patients receiving nutrition support should have their levels monitored more closely initially (e.g., every 6–12 hours) as they have a higher risk of developing hypophosphatemia, refeeding syndrome, and subsequent complications.30,122,125-128 Patients with renal insufficiency should have their serum phosphorus levels closely monitored because of the risk of hyperphosphatemia.

Hyperphosphatemia. Hyperphosphatemia is defined as a serum phosphorus concentration of >4.5 mg/dL. Serum phosphorus values should be interpreted cautiously since they may not correlate with total body stores of phosphorus. The most common cause of hyperphosphatemia in critically ill patients is renal insufficiency.25,26 Excessive i.v. or oral administration of phosphate, such as in ICU patients receiving specialized parenteral or enteral nutrition, can also cause hyperphosphatemia, especially in those with renal insufficiency.25,26,136-138 Severe hyperphosphatemia has been reported following treatment of constipation with phosphorus-containing laxatives in patients with compromised renal function.136,138 Other etiologies of hyperphosphatemia include acidosis (respiratory and metabolic), hemolysis, rhabdomyolysis, hypoparathyroidism, and vitamin D toxicity.25,26

The most common clinical manifestation of hyperphosphatemia is hypocalcemia due to calcium–phosphate precipitation, which can lead to tetany and other clinical manifestations of hypocalcemia.25,26 The risk of calcium–phosphate precipitation appears to increase when the serum calcium level multiplied by the serum phosphorus concentration exceeds 55–60 mg2/dL2.98,139,140 Calcium–phosphate crystals can also deposit into soft tissues and cause further organ damage.25,26,140,141

Treatment of hyperphosphatemia requires identification and correction of the underlying cause. The goals of therapy include returning the serum phosphorus concentration to normal (2.7–4.5 mg/dL), avoiding or resolving symptoms of hyperphosphatemia, and maintaining the serum (calcium × phosphorus) at <55–60 mg2/dL2.140,141 Daily phosphate intake (e.g., in parenteral or enteral nutrition formulas) must be adjusted for patients with renal insufficiency. Requirements may differ in patients receiving CRRT or intermittent hemodialysis because of the variation in the amount of phosphorus removed during these therapies. Oral phosphate binders, available as calcium, aluminum, and magnesium salts or as the non-ionic phosphate binder sevelamer, can be effective in lowering serum phosphorus levels. Table 5 lists suggested pharmacologic treatments of hyperphosphatemia.142-144

Phosphate binders, especially those containing magnesium and aluminum, should be used cautiously. Magnesium may cause diarrhea and aluminum may cause constipation. Both magnesium and aluminum may accumulate in patients with renal insufficiency and lead to toxicity. Therefore, calcium salts are preferred in patients with chronic renal insufficiency or when long-term therapy is required. Because it is significantly more expensive than other treatments, sevelamer should be reserved for use in hyperphosphatemia with hypercalcemia in chronic renal failure or hyperphosphatemia refractory to other treatments. Prolonged use of phosphate binders may paradoxically result in hypophosphatemia.

Because of the delayed onset of therapies for hyperphosphatemia, frequent monitoring of serum phosphorus levels is not usually needed. Routine monitoring of serum phosphorus levels (every 24–48 hours) is probably

Table 5. Pharmacologic Treatment of Hyperphosphatemia142-144

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage Forms</th>
<th>Initial Recommended Dosagea</th>
<th>Maximum Recommended Dosagea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium acetate</td>
<td>Tablet: 667 mg</td>
<td>2 tablets or gelcaps three times daily with meals</td>
<td>4 tablets or gelcaps with each meal daily; avoid hypercalcemia</td>
</tr>
<tr>
<td></td>
<td>Gelcap: 667 mg</td>
<td>1–2 g three times daily with meals</td>
<td>7 g/day; avoid hypercalcemia</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>Tablet, capsule, liquid, and powder; various strengths</td>
<td>1–2 tablets or 15–30 mL three or four times daily with meals and at bedtime</td>
<td>1800 mg (3–6 tablets) or 30 mL every 4 hr</td>
</tr>
<tr>
<td>Aluminum hydroxide</td>
<td>Tablets: 300 and 600 mg</td>
<td>1–2 tablets or 5–15 mL three times daily with meals</td>
<td>2–4 tablets four times daily with meals or 15 mL four times daily with meals and at bedtime</td>
</tr>
<tr>
<td></td>
<td>Suspension: 320 mg/5 mL</td>
<td></td>
<td>4000 mg three times daily with meals</td>
</tr>
<tr>
<td>Magnesium hydroxide</td>
<td>Tablets: 300 and 600 mg</td>
<td>1–2 tablets or 5–15 mL three times daily with meals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liquids: 400 and 800 mg/5 mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sevelamer</td>
<td>Tablets: 400 and 800 mg</td>
<td>800–1600 mg three times daily with meals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capsule: 403 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

aMay require higher doses in rare situations or in some patients with chronic renal insufficiency and severe hyperphosphatemia. The dosage should be adjusted to achieve the goal serum phosphorus level in these situations.
appropriate for most patients; patients with severe symptoms or those receiving renal replacement therapy may require more frequent monitoring.

**Calcium**

Calcium functions in bone metabolism, blood coagulation, platelet adhesion, neuromuscular activity, endocrine and exocrine secretory functions, and electrophysiology of the heart and smooth muscles. Serum calcium concentration is regulated by parathyroid hormone, vitamin D, and calcitonin. The normal range for total serum calcium concentration is 8.6–10.2 mg/dL.

About 99% of total body calcium is found in bones, with less than 1% in the serum. Approximately 40–50% of calcium in the blood is bound to plasma proteins, primarily albumin. Hypoalbuminemia, which is frequently seen in critically ill patients, can therefore cause a decrease in total serum calcium levels. For each 1-g/dL decrease in serum albumin concentration (below 4 g/dL), total serum calcium concentration decreases by approximately 0.8 mg/dL. Therefore, in patients with hypoalbuminemia the serum calcium concentration should be corrected for this. The corrected serum calcium concentration in patients with hypoalbuminemia can be estimated using the following equation:

\[
\text{Corrected serum calcium conc.} = \frac{\text{serum calcium conc.}}{4 - \text{serum albumin conc.}}
\]

Ionized or unbound calcium is the biologically active form of calcium and accounts for about 50% of calcium in the blood under normal conditions. Ionized serum calcium is closely regulated by the endocrine system and is a better indicator of the functional status of calcium metabolism than total calcium levels. Because of the poor correlation between ionized calcium and total calcium levels, especially in ICU patients with hypoalbuminemia or acid–base imbalance, direct measurement of ionized calcium concentration in critically ill ICU patients is recommended. The normal range for ionized serum calcium concentration is 1.12–1.30 mmol/L. Metabolic alkalosis increases calcium binding to plasma proteins, reducing the serum level of ionized calcium. Conversely, metabolic acidosis decreases calcium binding to plasma proteins, increasing the serum concentration of ionized calcium.

**Hypocalcemia.** Hypocalcemia (total serum calcium concentration of <8.6 mg/dL or ionized calcium concentration of <1.1 mmol/L) is primarily due to hypoalbuminemia. Other causes include hypomagnesemia, hyperphosphatemia, sepsis, pancreatitis, renal insufficiency, hypoparathyroidism, and administration of blood preserved with citrate. The hallmark sign of severe acute hypocalcemia is tetany. Other neuromuscular, CNS, and cardiovascular symptoms may be present, even with mild to moderate hypocalcemia. Signs and symptoms of chronic hypocalcemia include skin manifestations, such as brittle and grooved nails, hair loss, dermatitis, and eczema.

I.V. calcium gluconate and calcium chloride are used to treat hypocalcemia when rapid correction of serum calcium levels is required. Calcium gluconate provides three times more elemental calcium than an equivalent amount of calcium gluconate. Recent reports have described errors in calcium dosing and administration due to confusion over the calcium salt, dosage, and manner in which calcium was ordered, as well as potentially confusing product labels. We recommend that institutions establish a standardized method for ordering calcium to minimize the risk of dosing errors. Calcium gluconate should be used as the preferred salt for routine calcium maintenance and supplementation; calcium chloride should be restricted to use in urgent and emergent situations. One method to reduce the risk for errors associated with ordering and dosing of calcium is to order calcium gluconate in milliequivalents of calcium or in grams of calcium gluconate and to order calcium chloride in milliequivalents of calcium or in milligrams of calcium chloride. Regardless of the method used to order calcium salts, the terms “ampule,” “amp,” and “mL” should not be used to order the dosage of calcium, and the calcium salt should always be specified.

Calcium gluconate is also the preferred salt for peripheral venous administration since calcium chloride infusion may cause tissue necrosis if extravasation occurs. Calcium should not be infused in the same i.v. catheter as solutions containing phosphate because of the risk of calcium phosphate precipitation.

Asymptomatic hypocalcemia due to hypoalbuminemia requires no therapy. Severe hypocalcemia (total serum calcium concentration of <7.5 mg/dL or ionized calcium concentration of <0.9 mmol/L) or acute symptomatic hypocalcemia requires prompt correction with i.v. calcium administration. Initially, 1000 mg of calcium chloride (13.6 meq of calcium) or 3 g of calcium gluconate (13.7 meq of calcium) may be given over 10 minutes to control symptoms (Table 6). Since an i.v. bolus dose of calcium may only be effective for about two hours or less, severe acute hypocalcemia may not be corrected with intermittent i.v. bolus doses. Instead, a continuous infusion of i.v. calcium may be required, with close monitoring of serum calcium levels at least every six hours during the infusion. The infusion rate should not exceed 0.8–1.5 meq/min because of the potential risk for cardiac arrhythmias associated with rapid calcium infusion.

Typically, a calcium gluconate dose of 1–2 g (4.56–9.12 meq of calcium) is mixed in 100 mL of 5% dex-
Electrolyte disorders

Hypercalcemia. Hypercalcemia is defined as a total serum calcium concentration of >10.2 mg/dL and can be characterized as mild to moderate (total serum calcium concentration of 10.3–12.9 mg/dL) or severe (total serum calcium concentration of ≥13 mg/dL).

The primary causes of hypercalcemia are malignancy (e.g., breast cancer, lung cancer, multiple myeloma, non-Hodgkin’s lymphoma) and primary hyperparathyroidism.32,36 Certain medications (e.g., thiazide diuretics, lithium, vitamin A toxicity, vitamin D toxicity, milk-alkali syndrome, adrenal insufficiency, immobilization, Paget’s disease, rhabdomyolysis, and tuberculosis) can also cause hypercalcemia.32,36,37 Chronic hypercalcemia may cause nephrolithiasis, metastatic calcification, and renal failure.37

Mild hypercalcemia usually responds well to hydration and administration of i.v. calcium. Chronic or asymptomatic hypercalcemia can be treated with oral calcium supplements and vitamin D. Table 7 describes the calcium supplements available, their elemental calcium content, and the forms and routes.

Hypercalcemia frequently suffer from anorexia, fatigue, or confusion. Severe hypercalcemia may have cardiac manifestations, such as bradycardia or arrhythmias with ECG changes.31 Severe hypercalcemia or hypercalcemic crisis with a total serum calcium concentration of >13 mg/dL requires emergency treatment because it can lead to acute renal failure, obtundation, ventricular arrhythmias, coma, and death.33,34 Treatment should begin promptly, starting with i.v. hydration using 0.9% sodium chloride infusion at 200–300 mL/hr to reverse the intravascular volume contraction caused by hypercalcemia. After adequate hydration is achieved, furosemide 40–100 mg i.v. every one to four hours can be used to enhance renal calcium elimination and avoid fluid overload from the saline hydration, but caution should be taken to avoid further intravascular volume depletion. Saline hydration and furosemide can reduce serum calcium levels by about 2–3 mg/dL within the first 48 hours of treatment.359 Hemodialysis may be necessary in life-threatening hypercalcemia or in patients with impaired renal function.38

Bisphosphonates (e.g., etidronate, pamidronate, zoledronic acid) are potent inhibitors of bone resorption via action on osteoclast and osteoblast precursors and are frequently used for the treatment of hypercalcemia of malignancy. Etidronate disodium is effective when given intravenously at a dosage of 7.5 mg/kg/day over 2 hours for three to seven days. Pamidronate disodium is given as a single i.v. dose of 60–90 mg infused over 2–24 hours. The usual dose of zoledronic acid is a single i.v. dose of 4–8 mg infused over 15 minutes. Because of their prolonged time until onset of action, bisphosphonates have a limited role in the acute treatment of hypercalcemia; serum calcium levels usually begins to decline within two days of the first bisphos-

---

Table 6. Empirical Dosages of I.V. Calcium

<table>
<thead>
<tr>
<th>Degree of Hypocalcemia</th>
<th>Preferred Calcium Salt</th>
<th>Intermittent Bolus Dosage</th>
<th>Continuous Infusion Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild to moderate, asymptomatic</td>
<td>Gluconate</td>
<td>1–2 g calcium gluconate over 30–60 minutes; may repeat every 6 hours as needed</td>
<td>4.56–9.12 meq calcium over 30–60 minutes; may repeat every 6 hours as needed</td>
</tr>
<tr>
<td>Severe, symptomatic</td>
<td>Chloride or gluconate</td>
<td>1000 mg calcium chloride or 3 g calcium gluconate over 10 minutes; may repeat as needed</td>
<td>13.6 meq calcium over 10 minutes; may repeat as needed</td>
</tr>
<tr>
<td>Severe, symptomatic; refractory to intermittent bolus doses</td>
<td>Chloride or gluconate</td>
<td>Not applicable</td>
<td>0.8–1.5 meq calcium per minute; monitor serum calcium every 6 hours or more frequently</td>
</tr>
</tbody>
</table>

---

aCalcium chloride should be administered via a central venous catheter to avoid extravasation and tissue necrosis; 1000 mg calcium chloride = 13.6 meq calcium; 1 g calcium gluconate = 4.56 meq calcium.

bMaximum rate of intravenous infusion = 1.5 meq calcium per minute.
Electrolyte disorders

magnesium homeostasis, including

The normal serum magnesium body content in the extracellular fluid is primarily handled by the kidneys, but GI function, parathyroid hormone, and plasma magnesium concentrations also play a major role. Several other factors can affect magnesium homeostasis, including

the patient’s clinical condition, medications (e.g., loop diuretics, amphotericin B), and alcohol use.

Hypomagnesemia. Hypomagnesemia (serum magnesium concentration of <1.5 mg/dL) is frequently observed in critically ill patients and has been associated with increased mortality. Severe hypomagnesemia (serum magnesium concentration of <1.0 mg/dL) can result in ECG changes, arrhythmias (including torsades de pointes), seizures, coma, and even death. Hypomagnesemia may cause concomitant refractory hypokalemia and hypocalcemia. Although the exact mechanisms of these observations are unknown, hypokalemia is likely a result of impaired activity of the sodium–potassium pump, and hypocalcemia is likely due to impaired parathyroid release or activity.

Causes of hypomagnesemia include excessive GI losses, renal losses, surgery, trauma, infection or sepsis, burns, transfusion of blood preserved with citrate, starvation, malnutrition, alcoholism, and certain medications (e.g., thiazide and loop diuretics, aminoglycosides, amphotericin B, cisplatin, cyclosporine). Use of cardiac glycosides (e.g., digoxin) has also been associated with hypomagnesemia, possibly by enhancing magnesium excretion, and hypomagnesemia may potentiate digoxin toxicity (e.g., dysrhythmias).

Only about 1% of magnesium stores are found in the extracellular space, and serum magnesium levels may not correlate with intracellular concentrations or total body magnesium levels. Therefore, treatment of hypomagnesemia is largely empirical. Monitoring serum magnesium levels and monitoring the patient for resolution of signs and symptoms of hypomagnesemia are the most readily available method for assessing the effectiveness of magnesium supplementation. Because hypomagnesemia is observed frequently in critically ill patients and has been associated with increased mortality, the serum magnesium concentrations in critically ill patients in the ICU should be kept at 1.5 mg/dL or higher. Patients who have recently had an acute myocardial infarction may require higher concentrations (≥21.7 mg/dL) to prevent cardiac arrhythmias.

The goals of therapy should be to avoid or resolve symptoms, return the serum magnesium concentration to 1.5–2.4 mg/dL, and avoid hypermagnesemia. Oral magnesium supplements are available; however, problems with administration, slow onset of action, and GI intolerance may limit their utility. The i.v. route of administration is preferred, especially in critically ill patients with severe symptomatic hypomagnesemia. Few i.v. dosing regimens for the treatment and repletion of hypomagnesemia have been suggested. Magnesium deficiency has been associated with a total body magnesium deficiency of 1.0–2.0 meq/kg. Magnesium distributes into tissues slowly, but renal elimination is rapid, with up to 50% of an i.v. dose of magnesium excreted in the urine. Therefore, infusion time is critical, and additional supplementation may be required after the initial dose, with total repletion taking several days. For patients with mild to moderate hypomagnesemia, 8–32 meq of magnesium should be given (up to 1.0 meq/kg). Severe hypomagnesemia should be treated with 32–64 meq of magne-

<table>
<thead>
<tr>
<th>Table 7. Calcium Supplements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium Salt</td>
</tr>
<tr>
<td>Calcium chloride</td>
</tr>
<tr>
<td>Calcium gluconate</td>
</tr>
<tr>
<td>Calcium acetate</td>
</tr>
<tr>
<td>Calcium carbonate</td>
</tr>
<tr>
<td>Calcium citrate</td>
</tr>
</tbody>
</table>

*Maximum rate of i.v. infusion = 1.5 meq/min.
Electrolyte disorders

Doses of <6 g of magnesium sulfate should be infused over 8–12 hours, with higher doses infused over 24 hours. Because of the slow equilibration of magnesium between serum and intracellular spaces and tissues (e.g., bone, red blood cells, muscle),174 the serum magnesium levels could appear artificially high if measured too soon after a dose is given.174

We recommend administering 50% or less of the suggested empirically calculated magnesium dose in patients with renal insufficiency to decrease the risk of hypermagnesemia. For i.v. administration, the magnesium sulfate concentration should be diluted to 20% (20 g/100 mL) or less before administration, but the undiluted 50% solution may be administered intramuscularly to adults.175 Because a renal threshold for magnesium exists, with up to 50% of an i.v. dose being eliminated in the urine,44,45,169,170,173 i.v. magnesium sulfate should be administered at a maximum rate of 1 g/hr (8 meq of magnesium per hour) in asymptomatic patients with hypomagnesemia, and the total dose should not exceed 12 g (100 meq of magnesium) over 12 hours.169 Careful monitoring is also prudent, especially when doses approach the maximum recommendations.169 Rapid rates of magnesium infusion may exceed the renal threshold, resulting in increased urinary magnesium excretion and increasing the risk of adverse effects. Therefore, a lower rate of magnesium infusion may increase the fraction of the magnesium dose that is retained and decrease the risk of inducing hypermagnesemia.169,170,174

Severe symptomatic hypomagnesemia or conditions such as preeclampsia and eclampsia may require more aggressive magnesium therapy, with doses up to 4 g magnesium sulfate (32 meq of magnesium) over four to five minutes, with close monitoring.169,170 Serum magnesium levels should be monitored at least once daily during magnesium repletion, in addition to routine monitoring (every 24–48 hours).

**Hypermagnesemia.** Hypermagnesemia is defined as a serum magnesium concentration of >2.4 mg/dL. Generally, patients tolerate mild hypermagnesemia (serum magnesium concentration of 2.5–4 mg/dL) and are usually asymptomatic.44,47 Patients with moderate hypermagnesemia (4–12.5 mg/dL) may exhibit signs and symptoms, including nausea, vomiting, loss of deep tendon reflexes, hypotension, bradycardia, and ECG changes (e.g., increased PR interval, increased QRS interval duration).39,43,44,47 Severe hypermagnesemia (>12.5–32 mg/dL) can result in respiratory paralysis, refractory hypotension, atrioventricular block, cardiac arrest, and death.39,44,47,176 The most common causes of hypermagnesemia are renal insufficiency and iatrogenic causes.39,44

The primary therapy for hypermagnesemia is to discontinue exogenous magnesium administration. I.V. calcium should be administered to patients with severe symptomatic hypermagnesemia to reverse the cardiovascular and neuromuscular effects.44,47 I.V. calcium chloride doses of 500–1000 mg (7.8–13.6 meq of calcium) should be infused over 5–10 minutes and repeated until symptoms resolve. If the patient does not have a central venous catheter, 1–3 g of i.v. calcium gluconate (4.56–13.7 meq of calcium) should be infused over 3–10 minutes. Patients with asymptomatic hypermagnesemia may be treated with magnesium restriction, loop diuretics, or hemodialysis.44,47 Magnesium-containing antacids and other medications containing magnesium should be avoided in patients with renal insufficiency. Serum magnesium levels should be monitored at least once daily during treatment. More frequent monitoring may be required in asymptomatic patients when more aggressive therapy is used (e.g., loop diuretics, hemodialysis). Serum magnesium concentration should be maintained in the normal range (1.5–2.4 mg/dL) and hypomagnesemia avoided during treatment.

**Conclusion**

Treatment of electrolyte disorders is often empirical, based on published literature, expert opinion and recommendations, and the patient’s response to the initial treatment. Clinicians should be knowledgeable about electrolyte homeostasis and the underlying pathophysiology of electrolyte disorders to provide optimal therapy for patients.

**Table 8. Empirical Treatment of Hypomagnesemia**42,45,166-173

<table>
<thead>
<tr>
<th>Severity</th>
<th>Serum Magnesium Concentration (mg/dL)</th>
<th>I.V. Magnesium Replacement Dose&lt;sup&gt;a,b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild to moderate</td>
<td>1.0–1.5</td>
<td>8–32 meq magnesium (1–4 g magnesium sulfate), up to 1.0 meq/kg</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt;1.0</td>
<td>32–64 meq magnesium (4–8 g magnesium sulfate), up to 1.5 meq/kg</td>
</tr>
</tbody>
</table>

<sup>a</sup>In patients with normal renal function; patients with renal insufficiency should receive ≤50% of the initial empirical dose. Maximum rate of infusion = 8 meq magnesium per hour (1 g magnesium sulfate per hour), up to 100 meq magnesium (approximately 12 g magnesium sulfate) over 12 hours if asymptomatic; up to 32 meq magnesium (4 g magnesium sulfate) over 4–5 minutes in severe symptomatic hypomagnesemia. 1 g magnesium sulfate = 8.1 meq magnesium.

<sup>b</sup>The authors suggest using adjusted body weight (AdjBW) in patients who are significantly obese (weight of >130% of ideal body weight [IBW] or have a body mass index of ≥30 kg/m²): AdjBW (men) = (wt [kg] – IBW [kg]) × 0.3 + IBW; AdjBW (women) = (wt [kg] – IBW [kg]) × 0.25 + IBW.

**References**

Electrolyte disorders


